Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
Contineum Therapeutics (Nasdaq: CTNM), a clinical stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The company, which focuses on developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications, will be represented by its President and CEO, Carmine Stengone.
The conferences are:
- Morgan Stanley 22nd Annual Global Healthcare Conference (September 4-6, 2024, New York) - Presentation on September 4 at 7:00 am ET
- H.C. Wainwright 26th Annual Global Investment Conference (September 9-11, 2024, New York) - Presentation on September 10 at 2:30 pm ET
Both presentations will be available via webcast on Contineum's website, with replays accessible after the events conclude.
Contineum Therapeutics (Nasdaq: CTNM), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione a due prossimi conferenze per investitori. L'azienda, che si concentra sullo sviluppo di nuove terapie a piccole molecole per via orale per indicazioni in neuroscienze, infiammazione e immunologia, sarà rappresentata dal suo Presidente e CEO, Carmine Stengone.
Le conferenze sono:
- 22ª Conferenza Annuale Globale della Sanità di Morgan Stanley (4-6 settembre 2024, New York) - Presentazione il 4 settembre alle 7:00 ET
- 26ª Conferenza Annuale Globale sugli Investimenti di H.C. Wainwright (9-11 settembre 2024, New York) - Presentazione il 10 settembre alle 14:30 ET
Entrambe le presentazioni saranno disponibili tramite webcast sul sito web di Contineum, con registrazioni accessibili dopo la conclusione degli eventi.
Contineum Therapeutics (Nasdaq: CTNM), una empresa biofarmacéutica en fase clínica, ha anunciado su participación en dos próximas conferencias para inversores. La empresa, que se centra en el desarrollo de nuevas terapias orales de pequeñas moléculas para indicaciones en neurociencia, inflamación e inmunología, será representada por su presidente y CEO, Carmine Stengone.
Las conferencias son:
- 22ª Conferencia Anual Global de Atención Médica de Morgan Stanley (4-6 de septiembre de 2024, Nueva York) - Presentación el 4 de septiembre a las 7:00 am ET
- 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright (9-11 de septiembre de 2024, Nueva York) - Presentación el 10 de septiembre a las 2:30 pm ET
Ambas presentaciones estarán disponibles a través de una transmisión web en el sitio web de Contineum, con repeticiones accesibles después de que concluyan los eventos.
Contineum Therapeutics (Nasdaq: CTNM)는 임상 단계의 생명공학 회사로서 곧 있을 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 신경과학, 염증 및 면역학 적응증을 위한 새로운 구강 소분자 치료제 개발에 중점을 두고 있는 이 회사는 CEO이자 대통령인 카르미네 스텐곤이 대표할 것입니다.
회의 일정은 다음과 같습니다:
- 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스 (2024년 9월 4-6일, 뉴욕) - 9월 4일 오전 7:00 ET 발표
- H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스 (2024년 9월 9-11일, 뉴욕) - 9월 10일 오후 2:30 ET 발표
두 발표 모두 Contineum의 웹사이트를 통해 웹캐스트로 제공되며, 이벤트가 종료된 후에는 다시 볼 수 있습니다.
Contineum Therapeutics (Nasdaq: CTNM), une société biopharmaceutique en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise, qui se concentre sur le développement de nouvelles thérapies orales à petites molécules pour des indications en neurosciences, inflammation et immunologie, sera représentée par son président-directeur général, Carmine Stengone.
Les conférences sont :
- 22ème Conférence Annuelle Mondiale de la Santé de Morgan Stanley (4-6 septembre 2024, New York) - Présentation le 4 septembre à 7h00 ET
- 26ème Conférence Annuelle Mondiale des Investissements de H.C. Wainwright (9-11 septembre 2024, New York) - Présentation le 10 septembre à 14h30 ET
Les deux présentations seront disponibles en webdiffusion sur le site web de Contineum, avec des rediffusions accessibles après la fin des événements.
Contineum Therapeutics (Nasdaq: CTNM), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen, das sich auf die Entwicklung von neuen oralen Kleinmolekültherapien für Neurowissenschaften, Entzündungen und Immunologie konzentriert, wird von seinem Präsidenten und CEO, Carmine Stengone, vertreten.
Die Konferenzen sind:
- 22. Jährliche Globale Gesundheitskonferenz von Morgan Stanley (4.-6. September 2024, New York) - Präsentation am 4. September um 7:00 Uhr ET
- 26. Jährliche Globale Investorenkonferenz von H.C. Wainwright (9.-11. September 2024, New York) - Präsentation am 10. September um 14:30 Uhr ET
Beide Präsentationen werden über einen Webcast auf der Website von Contineum verfügbar sein, mit Aufzeichnungen, die nach Abschluss der Veranstaltungen zugänglich sind.
- None.
- None.
-
Morgan Stanley 22nd Annual Global Healthcare Conference, September 4-6, 2024, NY, NY:
- Carmine Stengone, Contineum’s President and CEO, will present on Wednesday, September 4, 2024, at 7:00 am ET.
-
H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, NY, NY:
- Carmine Stengone will present on Tuesday, September 10, 2024, at 2:30 pm ET.
The presentations will be available via webcast on the Investors section of Contineum’s website and a replay will be available following conclusion of the presentations.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of disease. Contineum has a pipeline of internally-developed programs to address multiple NI&I disorders. Contineum has two drug candidates in clinical trials, PIPE-791, an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS) and PIPE-307, a selective inhibitor of the M1 receptor, in clinical development for relapse remitting MS. PIPE-307 is being developed pursuant to a global license and development agreement between Contineum and Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, who has also announced plans to initiate a Phase 2 trial of PIPE-307 in depression in 2024.
Contineum is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828527257/en/
Company Contact:
Peter Slover
CFO
ir@contineum-tx.com
Source: Contineum Therapeutics, Inc.
FAQ
When is Contineum Therapeutics (CTNM) presenting at the Morgan Stanley Healthcare Conference?
What is the date and time of Contineum Therapeutics' (CTNM) presentation at the H.C. Wainwright Conference?
How can investors access Contineum Therapeutics' (CTNM) conference presentations?
What is the focus of Contineum Therapeutics' (CTNM) drug development efforts?
